Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Pharmacotherapeutic considerations in women with multiple sclerosis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{50dd020f2fbd4a85a7195226867960f5,
title = "Pharmacotherapeutic considerations in women with multiple sclerosis",
abstract = "INTRODUCTION: Multiple sclerosis (MS) is a chronically progressive disease of the central nervous system. The relapsing form of the disease predominantly affects women with onset between the ages 20 to 40 years. Therefore, timing, choice, and treatment options should take pregnancy planning into consideration to accommodate both the needs and safety of the mother and health of the fetus.AREAS COVERED: In this review, the authors discuss and summarize the recent evidence of different pharmacotherapeutic possibilities in the treatment of women with MS.EXPERT OPINION: There is evidence that disease modifying therapy reduces the risk of relapses and diminishes disability progression in people with relapsing MS. The disease is often diagnosed in the childbearing years, and thus pregnancy planning can possibly be a part of the pharmacotherapeutic considerations. The management of women planning pregnancy requires a balancing of risks. The clinician must consider the risks related to treatment discontinuation versus the risk of exposing the developing fetus to drugs that are potential fetotoxic. Randomized controlled trials of medication safety - if used during pregnancy, are prohibited for ethical reasons; hence, the evidence is continuously gathered from observational data, post-authorization studies and pregnancy registries.",
keywords = "Adult, Antibodies, Monoclonal/therapeutic use, Disease Progression, Female, Fertility/drug effects, Humans, Immunologic Factors/therapeutic use, Multiple Sclerosis, Relapsing-Remitting/drug therapy, Pregnancy, Pregnancy Complications/drug therapy, Pregnancy Outcome, Treatment Outcome, Young Adult, disease modifying therapy, multiple sclerosis, pregnancy, Pharmacotherapeutic considerations, women",
author = "Andersen, {Johanna B} and Melinda Magyari",
year = "2020",
month = sep,
doi = "10.1080/14656566.2020.1774554",
language = "English",
volume = "21",
pages = "1591--1602",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "13",

}

RIS

TY - JOUR

T1 - Pharmacotherapeutic considerations in women with multiple sclerosis

AU - Andersen, Johanna B

AU - Magyari, Melinda

PY - 2020/9

Y1 - 2020/9

N2 - INTRODUCTION: Multiple sclerosis (MS) is a chronically progressive disease of the central nervous system. The relapsing form of the disease predominantly affects women with onset between the ages 20 to 40 years. Therefore, timing, choice, and treatment options should take pregnancy planning into consideration to accommodate both the needs and safety of the mother and health of the fetus.AREAS COVERED: In this review, the authors discuss and summarize the recent evidence of different pharmacotherapeutic possibilities in the treatment of women with MS.EXPERT OPINION: There is evidence that disease modifying therapy reduces the risk of relapses and diminishes disability progression in people with relapsing MS. The disease is often diagnosed in the childbearing years, and thus pregnancy planning can possibly be a part of the pharmacotherapeutic considerations. The management of women planning pregnancy requires a balancing of risks. The clinician must consider the risks related to treatment discontinuation versus the risk of exposing the developing fetus to drugs that are potential fetotoxic. Randomized controlled trials of medication safety - if used during pregnancy, are prohibited for ethical reasons; hence, the evidence is continuously gathered from observational data, post-authorization studies and pregnancy registries.

AB - INTRODUCTION: Multiple sclerosis (MS) is a chronically progressive disease of the central nervous system. The relapsing form of the disease predominantly affects women with onset between the ages 20 to 40 years. Therefore, timing, choice, and treatment options should take pregnancy planning into consideration to accommodate both the needs and safety of the mother and health of the fetus.AREAS COVERED: In this review, the authors discuss and summarize the recent evidence of different pharmacotherapeutic possibilities in the treatment of women with MS.EXPERT OPINION: There is evidence that disease modifying therapy reduces the risk of relapses and diminishes disability progression in people with relapsing MS. The disease is often diagnosed in the childbearing years, and thus pregnancy planning can possibly be a part of the pharmacotherapeutic considerations. The management of women planning pregnancy requires a balancing of risks. The clinician must consider the risks related to treatment discontinuation versus the risk of exposing the developing fetus to drugs that are potential fetotoxic. Randomized controlled trials of medication safety - if used during pregnancy, are prohibited for ethical reasons; hence, the evidence is continuously gathered from observational data, post-authorization studies and pregnancy registries.

KW - Adult

KW - Antibodies, Monoclonal/therapeutic use

KW - Disease Progression

KW - Female

KW - Fertility/drug effects

KW - Humans

KW - Immunologic Factors/therapeutic use

KW - Multiple Sclerosis, Relapsing-Remitting/drug therapy

KW - Pregnancy

KW - Pregnancy Complications/drug therapy

KW - Pregnancy Outcome

KW - Treatment Outcome

KW - Young Adult

KW - disease modifying therapy

KW - multiple sclerosis

KW - pregnancy

KW - Pharmacotherapeutic considerations

KW - women

UR - http://www.scopus.com/inward/record.url?scp=85087017964&partnerID=8YFLogxK

U2 - 10.1080/14656566.2020.1774554

DO - 10.1080/14656566.2020.1774554

M3 - Review

C2 - 32521172

VL - 21

SP - 1591

EP - 1602

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 13

ER -

ID: 61976062